



ABN 53 075 582 740

ASX ANNOUNCEMENT

21 August 2017

Bionomics & MSD 5th Annual Neuroscience Symposium in October

- **One day program titled *The Frontiers of Neuroscience: Feelings & Forgetting***
- **In conjunction with the national AusBiotech 2017 conference to be held in Adelaide**

Bionomics Limited (ASX:BNO, OTCQX:BNOEF), a biopharmaceutical company focused on the discovery and development of innovative therapeutics for the treatment of diseases of the central nervous system (CNS) and cancer, will again co-host its annual neuroscience symposium with MSD in Adelaide.

The one-day event at the Adelaide Convention Centre on 26 October is entitled *The Frontiers of Neuroscience: Feelings & Forgetting* featuring world-renowned industry experts.

Bionomics and MSD (known as Merck, in the United States and Canada) collaborate to arrange this event.

The annual Bionomics-MSD symposium is in its fifth year and has demonstrated year on year growth in participation numbers. Last year's event entitled *Frontiers in Neuroscience Research: Memory, Movement and Mood* attracted over 200 delegates including researchers, medical personnel, patient support groups, life science analysts and investors. The purpose of this event continues to focus on the importance of finding suitable treatment options for cognitive conditions and keeping participants informed of the latest advances.

The symposium will be opened by Bionomics CEO and Managing Director, Dr Deborah Rathjen and closed by Mr Ben Thorner, Senior Vice President, Business Development & Licensing at MSD.

Some of the key presentations at the symposium this year will be;

- Professor Steve Williams, IoPPN Kings College London & Maudsley Hospital on *MR Neuroimaging to Facilitate the Drug R&D Process - from Mouse to Man*
- Professor Ole Isaacson Professor of Neurology & Neuroscience, Harvard Medical School on *Novel Concepts from Human Cell Biology and Genetics for Neurodegenerative Disease Treatments*
- Dr Richard Hargreaves, Corporate Vice President Neuroscience & Imaging, Celgene on *Seeing the Problems and Devising Solutions for Neurodegenerative Disease*

There will be emphasis upon the treatment of post-traumatic stress disorder (PTSD) at the symposium this year with Professor Malcolm Hopwood, Ramsay Health Care Professor of

Psychiatry, University of Melbourne on *PTSD: Treatment Opportunities*. This presentation will be followed by Dr Sue O'Connor VP Neuroscience from Bionomics who will present an overview on lead drug candidate BNC210 and its potential as a viable anxiolytic – *A Novel Therapeutic in Development for PTSD*.

Please find the full program below, registration is free of charge and interested individuals can contact Dr Lauren Nicotra, Senior Associate, Strategic Alliances at symposium@bionomics.com.au to enquire about registration.

FOR FURTHER INFORMATION PLEASE CONTACT:

Australia

Monsoon Communications
Rudi Michelson
+613 9620 3333
rudim@monsoon.com.au

US

Stern Investor Relations
Beth DelGiacco
+1 212 362 1200
beth@sternir.com

About Bionomics Limited

Bionomics (ASX: BNO) is a global, clinical stage biopharmaceutical company leveraging its proprietary platform technologies to discover and develop a deep pipeline of best in class, novel drug candidates focused on the treatment of serious central nervous system disorders and on the treatment of cancer. Bionomics' lead drug candidate BNC210, currently in Phase 2 for the treatment of generalized anxiety disorder and for post-traumatic stress disorder, is a novel, proprietary negative allosteric modulator of the alpha-7 ($\alpha 7$) nicotinic acetylcholine receptor. The company is also developing BNC101, its lead humanized monoclonal antibody targeting a key receptor on cancer stem cells that is overexpressed in metastatic colorectal cancer, metastatic pancreatic cancer and many other solid tumours; BNC101 entered clinical trials in the first quarter of 2016. Bionomics has strategic partnerships with Merck & Co., Inc (known as MSD outside the United States and Canada).
www.bionomics.com.au

Factors Affecting Future Performance

This announcement contains "forward-looking" statements within the meaning of the United States' Private Securities Litigation Reform Act of 1995. Any statements contained in this announcement that relate to prospective events or developments, including, without limitation, statements made regarding Bionomics' drug candidates (including BNC210 and BNC101), its licensing agreements with Merck & Co. and any milestone or royalty payments thereunder, drug discovery programs, ongoing and future clinical trials, and timing of the receipt of clinical data for our drug candidates are deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions are intended to identify forward-looking statements.

There are a number of important factors that could cause actual results or events to differ materially from those indicated by these forward-looking statements, including unexpected safety or efficacy data, unexpected side effects observed in clinical trials, risks related to our available funds or existing funding arrangements, our failure to introduce new drug candidates or platform technologies or obtain regulatory approvals in a timely manner or at all, regulatory changes, inability to protect our intellectual property, risks related to our international operations, our inability to integrate acquired businesses and technologies into our existing business and to our competitive advantage, as well as other factors. Results of studies performed on our drug candidates and competitors' drugs and drug candidates may vary from those reported when tested in different settings.

5th Annual Symposium

The Frontiers of Neuroscience: Feelings & Forgetting

Adelaide Convention Centre, North Terrace, Adelaide
Thursday 26 October 2017

Free registration (email Lauren Nicotra: symposium@bionomics.com.au)

Time	Speaker	Topic
SESSION 1:		
9.15	Dr Deborah Rathjen CEO & Managing Director, Bionomics	Welcome
9.30	Professor Steve Williams IoPPN Kings College London & Maudsley Hospital	MR Neuroimaging to Facilitate the Drug R&D Process - from Mouse to Man
10.00	Dr Ann Hayes The Ann Hayes Consultancy; formerly Director of CNS Therapeutic Research, GlaxoWellcome	Multiple Mechanisms for Pain – How Can We Improve the Chances of Success?
10.30	MORNING TEA	
SESSION 2:		
11.00	Dr Richard Hargreaves Corporate Vice President Neuroscience & Imaging, Celgene	Seeing the Problems and Devising Solutions for Neurodegenerative Disease
11.30	Professor Ole Isaacson Professor of Neurology & Neuroscience, Harvard Medical School	Novel Concepts from Human Cell Biology and Genetics for Neurodegenerative Disease Treatments
12.00	Dr Michael F Egan Associate Vice President, Clinical Neuroscience, MSD	Development of BACE Inhibitors for the Treatment of Alzheimer's Disease
12.30	LUNCH	
SESSION 3:		
1.30	Dr Paul Coleman Executive Director, Discovery Chemistry, MSD	Discovery of Belsomra, a First-in-Class Orexin Antagonist for the Treatment of Insomnia
2.00	Professor Alexander McFarlane Director of the Centre for Traumatic Stress Studies, Professor of Psychiatry, University of Adelaide	The Importance of a Staging Approach to Psychiatric Illness in Understanding the Role of Biomarkers and Treatment Response
2.30	Professor Paul Rolan Director of Innovation, University of Adelaide	Innovation in Clinical Trial Design
3.00	AFTERNOON TEA	
SESSION 4:		
3.30	Professor Malcolm Hopwood Ramsay Health Care Professor of Psychiatry, University of Melbourne	PTSD: Treatment Opportunities
4.00	Dr Sue O'Connor VP Neuroscience, Bionomics	BNC210 – A Novel Therapeutic in Development for PTSD
4.30	Mr Ben Thorner Senior Vice President, Business Development & Licensing, MSD	Close
4.45-5.45	NETWORKING WITH DRINKS & CANAPES	